Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03957239
Other study ID # IRB201901253
Secondary ID OCR21702
Status Completed
Phase N/A
First received
Last updated
Start date September 5, 2019
Est. completion date January 2, 2020

Study information

Verified date January 2020
Source University of Florida
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

In this double blind, crossover study participants will consume a cranberry beverage and a cranberry-flavored beverage for 2 weeks each. Gut permeability will be assessed weekly using aspirin and food-grade sugar molecules. Participants will be asked to provide urine, blood, saliva and stool samples to assess gut permeability and microbial communities. No change in permeability to the small sugar probes is anticipated with the cranberry beverage


Description:

Obesity, stress, liver disease, alcoholism, diabetes, and autoimmune diseases in humans or animal models are associated with altered intestinal permeability; consequently, maintenance of the gastrointestinal barrier is an emerging area of interest. The purpose of this randomized, double-blind, controlled crossover study is to compare the difference between the change from baseline in gastroduodenal permeability after drinking a cranberry or control beverage for two weeks. Gastroduodenal permeability will be assessed following aspirin challenge by measuring urinary sucrose in the 0 to 5-hour urine collection after differential sugar probes are consumed. Urine will be collected for an additional 19 hours (24 hours total) to assess whole gut permeability. A 4-week washout period will separate the interventions. Stool and fasting blood and saliva samples will be obtained before and during the intervention periods to assess fecal microbial communities and markers of intestinal barrier, immune function and oxidative stress. It is anticipated that cranberry juice will selectively increase intestinal Akkermansia bacteria, reduce markers of inflammation and oxidative stress, increase mucosal immunity, and protect the gastroduodenal barrier from an aspirin challenge.


Recruitment information / eligibility

Status Completed
Enrollment 43
Est. completion date January 2, 2020
Est. primary completion date January 2, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 21 Years to 50 Years
Eligibility Inclusion Criteria

- Have a BMI = 30 kg/m2 and a waist circumference = 35 inches for women and = 40 inches for men.

- Have had a stable weight for 3 months (<5 kg or ~11 lbs body weight change)

- Willing to discontinue the use of non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, aspirin, naproxen, or indomethacin, for the full length of the study.

- Willing to discontinue consumption of wine and berries throughout the 12-week study.

- Willing and able to avoid consumption of any cranberry juice, whole cranberries, and dried cranberries during the two weeks leading up to the study and during the study, not including the study beverage.

- Willing to avoid beer and cocktails on the day before and the day of the sugar probe tests.

- Willing to avoid the use of antidiarrheal or laxative medication on a regular or an "as-needed basis" during the full length of the study.

- Willing to provide urine, saliva, blood, and stool samples during the study collection periods.

- Have used aspirin in the past and did not experience adverse effects.

- Willing to consume three tablets (325 mg each or 975 mg total) twice within a 9 to 12-hour period. This challenge will be repeated four times during the 12-week study.

- Willing and able to complete daily and weekly questionnaires online regarding dietary intake and general health and well-being, including gastrointestinal habits.

- Willing to discontinue consumption of fermented foods or probiotics.

- Willing to discontinue consumption of fiber supplements.

- Willing to discontinue taking prebiotic, herbal, or high-dose vitamin or mineral supplements that may impact immune function or inflammation during the pre-baseline period and throughout the study protocol.

- Willing and able to consume 4.23 oz of a cranberry beverage four times daily (~16 oz total/d) for the 2-week study interventions.

- Willing to avoid high intensity exercises two days prior to and the day of the permeability tests. These tests will be done on four occasions.

- Willing and able to complete the informed consent form in English.

- Willing to provide a social security number to receive study payment.

Exclusion Criteria

- Currently being treated for a physician-diagnosed gastrointestinal disease or condition (such as ulcerative colitis, Crohn's disease, gastroparesis, cancer, peptic ulcer disease, Celiac disease, short bowel disease, ileostomy, or colostomy) other than GERD or diverticular disease

- Currently being treated for or type 1 diabetes or type 2 diabetes by medication

- Daily use of NSAIDs in the last 3 months or incidental use in the last 2 weeks prior to screening.

- Allergy to aspirin or cranberries.

- Participate in moderate or high exercise activities during a typical week.

- Currently smoking (including vaping) tobacco products

- Women who are lactating, pregnant, or are attempting to get pregnant.

- Use of another investigational product within 3 months of the screening visit.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Cranberry Beverage
The cranberry beverage will provide 50 kcals and 4.0 grams of fiber per day from whole milled cranberries, water, cranberry natural flavor and sucralose.
Control Beverage
The control beverage will provide 50 kcals per day and is a color, taste matched sugar sweetened beverage formulated with water, sucrose, citric acid, cranberry natural flavor, malic acid, xanthum gum, sucralose and artificial color (red 40, blue 1).

Locations

Country Name City State
United States UF Health at the University of Florida Gainesville Florida

Sponsors (2)

Lead Sponsor Collaborator
University of Florida Ocean Spray, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Gastroduodenal permeability Compare the statistical difference between the change from baseline (i.e., final - baseline) in gastroduodenal permeability after consuming the cranberry beverage for 2 weeks versus the change after consuming the control beverage for 2 weeks. Gastroduodenal permeability will be assessed following aspirin challenge by measuring urinary sucrose in the 0 to 5-hour urine collection. Baseline and Week 2 of each intervention
Secondary Change in Small intestinal permeability Compare the difference between the changes in lactulose/rhamnose concentrations in a 5-hour urine collection (end of intervention minus baseline) from the cranberry beverage versus control beverage Baseline and Week 2 of each intervention
Secondary Change in Colonic permeability Compare the difference between the changes in sucralose/ erythritol ratio in the 5 to 24-hour urine collection (end of intervention minus baseline) from the cranberry beverage vs control beverage Baseline and Week 2 of each intervention
Secondary Change in Whole gut permeability Compare the difference between the changes in sucralose/ erythritol ratio in the 0 to 24-hour urine collection (end of intervention minus baseline) from the cranberry beverage vs control beverage Baseline and Week 2 of each intervention
Secondary Change in Stool consistency Compare the average stool consistency (Bristol Stool Form Scale) between the cranberry beverage versus control beverage. The Bristol Stool Form Scale (BSS) measures stool types from 1-7 with 1 = hard and 7 = liquid. A score from 3-5 is indicative of a normal BSS. Baseline and Week 2 of each intervention
Secondary Change in Stool frequency Compare the number of number of stools between the cranberry beverage versus control beverage Baseline and Week 2 of each intervention
Secondary Change in Bacterial species of interest Compare the genome equivalents between the cranberry beverage versus control beverage. Genome equivalents will be measured by quantitative polymerase chain reaction. Baseline and Week 2 of each intervention
See also
  Status Clinical Trial Phase
Recruiting NCT04543877 - WHNRC (Western Human Nutrition Research Center) Fiber Intervention Study Early Phase 1
Recruiting NCT04109352 - Labelled Carbon Sucrose Breath Test (13C-SBT) as a Marker of Environmental Enteropathy
Completed NCT01424306 - Diet and Systemic Inflammation N/A
Completed NCT01241201 - Intestinal Barrier Function and Probiotics. N/A
Completed NCT01477034 - Vitamin D and Adipose Tissue Inflammation N/A
Recruiting NCT05257200 - Gut Permeability and Bariatric-metabolic Surgery
Completed NCT03027583 - The Effect of Probiotic Intervention on Intestinal Permeability N/A
Completed NCT03704727 - The Effects of Probiotics on Intestinal Permeability in Gastrointestinal Cancer Patients in Chemotherapy N/A
Completed NCT01049386 - Intestinal Permeability Phase 2
Recruiting NCT04979130 - Comparing Semaglutide Versus Placebo on Intestinal Barrier Function in Type 2 Diabetes Mellitus (SIB) Phase 4
Recruiting NCT06262880 - Dietary Supplementation on Gastrointestinal Barrier Function N/A
Completed NCT01756040 - Intestinal Permeability in Preterm Infants Phase 1
Active, not recruiting NCT04083950 - Induction of Gut Permeability by an Oral Vaccine Early Phase 1
Completed NCT03113240 - Trial of Enteral Glutamine on Intestinal Permeability in Critically Ill Patients Phase 3